


## Moving Forward in Metastatic NSCLC: the Role of ADCs

Friday 22 March 2024,  
18:45 – 20:15 CET

South Hall 2, Prague Congress Centre,  
Prague, Czech Republic



**In this symposium, our experts will discuss the potential of ADCs for the treatment of NSCLC.**

The expert panel, chaired by Prof. Reck, will present the current standard of care and unmet needs in NSCLC, the role of ADCs and future challenges in this disease, considering the novel targets being explored.

Finally, a discussion among the panelists will close the session.

We look forward to welcoming you!



**Martin Reck**

*(Chair)*

Lung Clinic,  
Department of Thoracic Oncology,  
Grosshansdorf, Germany



**Enriqueta Felip**

Lung Cancer Unit,  
Oncology Department,  
Vall d'Hebron University Hospital,  
Barcelona, Spain



**Anna Minchom**

Drug Development Unit,  
Royal Marsden Hospital and The Institute  
of Cancer Research, London, UK

### Agenda

Welcome and Introduction

Martin Reck

From the Current Status to Unmet Needs

Martin Reck

ADCs in Late-Stage Development: Who Can Benefit?

Enriqueta Felip

Beyond the Horizon: Unveiling Novel ADC Targets

Anna Minchom

Panel Discussion and Audience Q&A

All panel members

Closing Remarks

Martin Reck

ADC, antibody-drug conjugate  
NSCLC, non-small cell lung cancer

SEAGEN and its logos are trademarks of Seagen Inc., registered in the European Union and elsewhere.  
©2023 Seagen Inc. USA. All rights reserved.

Date of preparation: December 2023 | CZ/ADC/2023/0005

